ZBH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.22B

+9.9%

2.395

+3.69%

2.07B

+8.18%

1.922

+6.17%

2.18B

+4.98%

2.114

+2.11%

Estimates Revision

The market is revising Downward the revenue expectations for Zimmer Biomet Holdings, Inc. (ZBH) for FY2025, with the revenue forecasts being adjusted by -0.11% over the past three months. During the same period, the stock price has changed by -3.38%.

Revenue Estimates for FY2025

Revise Downward

-0.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.18%

In Past 3 Month

Stock Price

Go Down

-3.38%

In Past 3 Month

19 Analyst Rating

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 103.38 USD with a low forecast of 88.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

12 Hold

2 Sell

Hold

Current: 0.000

Low

88.00

Averages

103.38

High

130.00

Current: 0.000

Low

88.00

Averages

103.38

High

130.00

Goldman Sachs

David Roman

Neutral -> Sell

downgrade

$97 -> $93

2026-01-09

New

Reason

Goldman Sachs

David Roman

Price Target

$97 -> $93

2026-01-09

New

downgrade

Neutral -> Sell

Reason

Goldman Sachs analyst David Roman downgraded Zimmer Biomet to Sell from Neutral with a price target of $93, down from $97. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. While the shares underperformed in 2025 on top-line growth deceleration and downside variance to quarterly organic growth estimates, Goldman does not expect an improvement in 2026.

Bernstein

Market Perform

maintain

$97 -> $99

2026-01-09

New

Reason

Bernstein

Price Target

$97 -> $99

2026-01-09

New

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Zimmer Biomet to $99 from $97 and keeps a Market Perform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Raymond James

Outperform -> Market Perform

downgrade

2026-01-06

New

Reason

Raymond James

Price Target

2026-01-06

New

downgrade

Outperform -> Market Perform

Reason

Raymond James downgraded Zimmer Biomet to Market Perform from Outperform without a price target. The firm is "frustrated" with the company's inconsistent growth and believes this dynamic may persist in 2026. Zimmer's revenue growth will remain challenged, and with its margins optimized, a slower revenue growth profile will temper earnings growth, the analyst tells investors in a research note.

Evercore ISI

In Line -> Outperform

upgrade

$94 -> $120

2026-01-05

New

Reason

Evercore ISI

Price Target

$94 -> $120

2026-01-05

New

upgrade

In Line -> Outperform

Reason

Evercore ISI upgraded Zimmer Biomet to Outperform from In Line with a price target of $120, up from $94.

JPMorgan

Neutral

maintain

$100

2025-12-23

Reason

JPMorgan

Price Target

$100

2025-12-23

maintain

Neutral

Reason

JPMorgan thinks 2026 is set up to be a "pivotal year" for Zimmer Biomet. The analyst keeps a Neutral rating on the shares with a $100 price target. Investors want Zimmer to "deliver a boring, consistent, beat and raise year" where results outperform expectations, the analyst tells investors in a research note. After meeting with management, JPMorgan thinks the company's fundamentals are in "good shape, with portfolio gaps filled and plenty of opportunities for growth." It views Zimmer's 2026 as conservative and sees potential for a year for the stock.

Baird

Jeff Johnson

Outperform -> Neutral

downgrade

$117 -> $100

2025-12-16

Reason

Baird

Jeff Johnson

Price Target

$117 -> $100

2025-12-16

downgrade

Outperform -> Neutral

Reason

Baird analyst Jeff Johnson downgraded Zimmer Biomet to Neutral from Outperform with a price target of $100, down from $117. The firm adjusted ratings and medical technology as part of its 2026 outlook. Zimmer's "disappointing" 2025 despite good initial new product uptake brings questions around potential Mako surgeon gains for Stryker likely impacting the company, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Zimmer Biomet Holdings Inc (ZBH.N) is 10.73, compared to its 5-year average forward P/E of 15.80. For a more detailed relative valuation and DCF analysis to assess Zimmer Biomet Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.80

Current PE

10.73

Overvalued PE

18.70

Undervalued PE

12.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.20

Current EV/EBITDA

8.91

Overvalued EV/EBITDA

14.19

Undervalued EV/EBITDA

10.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.27

Current PS

2.09

Overvalued PS

3.87

Undervalued PS

2.67

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ZBH News & Events

Events Timeline

No data

News

1.0

2025-12-22Newsfilter

Zimmer Biomet to Present at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

1.0

2025-12-22PRnewswire

Zimmer Biomet to Present at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

8.0

2025-12-17NASDAQ.COM

Maximizing Zimmer Biomet Holdings' Yield from 1% to 11.7% Through Options Strategies

People Also Watch

Frequently Asked Questions

What is Zimmer Biomet Holdings Inc (ZBH) stock price today?

The current price of ZBH is 94.08 USD — it has increased 1.52 % in the last trading day.

What is Zimmer Biomet Holdings Inc (ZBH)'s business?

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

What is the price predicton of ZBH Stock?

What is Zimmer Biomet Holdings Inc (ZBH)'s revenue for the last quarter?

Zimmer Biomet Holdings Inc revenue for the last quarter amounts to 2.00B USD, increased 9.71 % YoY.

What is Zimmer Biomet Holdings Inc (ZBH)'s earnings per share (EPS) for the last quarter?

Zimmer Biomet Holdings Inc. EPS for the last quarter amounts to 1.16 USD, decreased -5.69 % YoY.

What changes have occurred in the market's expectations for Zimmer Biomet Holdings Inc (ZBH)'s fundamentals?

How many employees does Zimmer Biomet Holdings Inc (ZBH). have?

Zimmer Biomet Holdings Inc (ZBH) has 17000 emplpoyees as of January 09 2026.

What is Zimmer Biomet Holdings Inc (ZBH) market cap?

Today ZBH has the market capitalization of 18.64B USD.